MX360206B - Compuestos inmunogenicos que comprenden peptido de proteina transmembrana 41 (gp41) del virus de inmunodeficiencia humana (vih) acoplado a proteina transportadora crm197. - Google Patents

Compuestos inmunogenicos que comprenden peptido de proteina transmembrana 41 (gp41) del virus de inmunodeficiencia humana (vih) acoplado a proteina transportadora crm197.

Info

Publication number
MX360206B
MX360206B MX2014014526A MX2014014526A MX360206B MX 360206 B MX360206 B MX 360206B MX 2014014526 A MX2014014526 A MX 2014014526A MX 2014014526 A MX2014014526 A MX 2014014526A MX 360206 B MX360206 B MX 360206B
Authority
MX
Mexico
Prior art keywords
protein
hiv
crm197
coupled
immunodeficiency virus
Prior art date
Application number
MX2014014526A
Other languages
English (en)
Spanish (es)
Other versions
MX2014014526A (es
Inventor
Ho Tsong Fang Raphaël
Desfontaines Dominique
Crouzet Joël
Original Assignee
Innavirvax
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innavirvax filed Critical Innavirvax
Publication of MX2014014526A publication Critical patent/MX2014014526A/es
Publication of MX360206B publication Critical patent/MX360206B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K17/00Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02Peptides being immobilised on, or in, an organic carrier
    • C07K16/1145
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036Retroviridae, e.g. leukemia viruses
    • C07K16/1045Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6081Albumin; Keyhole limpet haemocyanin [KLH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/62Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
MX2014014526A 2012-05-31 2013-05-30 Compuestos inmunogenicos que comprenden peptido de proteina transmembrana 41 (gp41) del virus de inmunodeficiencia humana (vih) acoplado a proteina transportadora crm197. MX360206B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305602.0A EP2668959B1 (en) 2012-05-31 2012-05-31 Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein
PCT/IB2013/054482 WO2013179262A1 (en) 2012-05-31 2013-05-30 Immunogenic compounds comprising hiv gp41 peptide coupled to crm197 carrier protein

Publications (2)

Publication Number Publication Date
MX2014014526A MX2014014526A (es) 2015-06-02
MX360206B true MX360206B (es) 2018-10-24

Family

ID=48793339

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014526A MX360206B (es) 2012-05-31 2013-05-30 Compuestos inmunogenicos que comprenden peptido de proteina transmembrana 41 (gp41) del virus de inmunodeficiencia humana (vih) acoplado a proteina transportadora crm197.

Country Status (21)

Country Link
US (1) US9511136B2 (cg-RX-API-DMAC7.html)
EP (2) EP2668959B1 (cg-RX-API-DMAC7.html)
JP (1) JP6352251B2 (cg-RX-API-DMAC7.html)
KR (1) KR102077876B1 (cg-RX-API-DMAC7.html)
CN (1) CN104507496B (cg-RX-API-DMAC7.html)
AU (1) AU2013269120B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014029861B1 (cg-RX-API-DMAC7.html)
CA (1) CA2875162C (cg-RX-API-DMAC7.html)
DK (1) DK2668959T3 (cg-RX-API-DMAC7.html)
EA (1) EA027803B1 (cg-RX-API-DMAC7.html)
ES (2) ES2528109T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20150058T1 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN10128A (cg-RX-API-DMAC7.html)
MX (1) MX360206B (cg-RX-API-DMAC7.html)
PL (1) PL2668959T3 (cg-RX-API-DMAC7.html)
PT (1) PT2668959E (cg-RX-API-DMAC7.html)
RS (1) RS53769B1 (cg-RX-API-DMAC7.html)
SI (1) SI2668959T1 (cg-RX-API-DMAC7.html)
UA (1) UA118542C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013179262A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201409023B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335119A1 (en) * 2004-02-06 2014-11-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL
TWI740823B (zh) * 2015-04-17 2021-10-01 澳大利亞商保健樂科技昆士蘭有限公司 疫苗組成物及其用途
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184973A1 (en) * 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
EP3574915A1 (en) * 2018-05-29 2019-12-04 Neovacs Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity
EP4115900A1 (en) * 2021-07-05 2023-01-11 Diaccurate Novel antigens and vaccines

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1445614A1 (en) * 2003-02-06 2004-08-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for the in vitro assessment of the progression status of an HIV virus in an invidual
TWI379839B (en) * 2003-12-17 2012-12-21 Wyeth Llc Aβ immunogenic peptide carrier conjugates and methods of producing same
WO2010022740A2 (en) * 2008-08-28 2010-03-04 Aarhus Universitet Hiv-1 envelope polypeptides for hiv vaccine
US7965010B2 (en) * 2008-09-03 2011-06-21 Bose Corporation Linear motor with patterned magnet arrays
WO2010040853A1 (en) * 2008-10-10 2010-04-15 INSERM (Institut National de la Santé et de la Recherche Médicale) A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method

Also Published As

Publication number Publication date
KR20150032266A (ko) 2015-03-25
US9511136B2 (en) 2016-12-06
PL2668959T3 (pl) 2015-04-30
CN104507496A (zh) 2015-04-08
EP2854846A1 (en) 2015-04-08
AU2013269120B2 (en) 2017-04-20
WO2013179262A1 (en) 2013-12-05
AU2013269120A1 (en) 2014-12-18
PT2668959E (pt) 2015-02-05
CA2875162C (en) 2021-09-14
ES2528109T3 (es) 2015-02-04
BR112014029861A2 (pt) 2017-07-25
IN2014DN10128A (cg-RX-API-DMAC7.html) 2015-08-21
UA118542C2 (uk) 2019-02-11
KR102077876B1 (ko) 2020-02-14
EP2668959A1 (en) 2013-12-04
US20150147348A1 (en) 2015-05-28
EA201491969A1 (ru) 2015-04-30
RS53769B1 (sr) 2015-06-30
CN104507496B (zh) 2018-08-03
EA027803B1 (ru) 2017-09-29
JP6352251B2 (ja) 2018-07-04
HRP20150058T1 (hr) 2015-04-10
ZA201409023B (en) 2016-08-31
ES2701084T3 (es) 2019-02-20
MX2014014526A (es) 2015-06-02
EP2854846B1 (en) 2018-09-12
CA2875162A1 (en) 2013-12-05
SI2668959T1 (sl) 2015-03-31
DK2668959T3 (en) 2015-01-26
JP2015519359A (ja) 2015-07-09
BR112014029861B1 (pt) 2022-05-24
EP2668959B1 (en) 2014-11-05

Similar Documents

Publication Publication Date Title
MX2021011394A (es) Compuestos de carbamoilpiridona triciclica puenteada y su uso farmaceutico.
MX360206B (es) Compuestos inmunogenicos que comprenden peptido de proteina transmembrana 41 (gp41) del virus de inmunodeficiencia humana (vih) acoplado a proteina transportadora crm197.
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
ECSP14013315A (es) Inhibidores de aplicación viral
CO2019001379A2 (es) Compuestos terapéuticos útiles para el tratamiento profiláctico o terapéutico de una infección por el virus del vih .
CO2020002980A2 (es) Agentes antivirales contra la hepatitis b.
GT201300093A (es) Compuestos antivirales
UY37997A (es) Agentes antivirales contra la hepatitis b
CO7170160A2 (es) Nuevas 6-aminoacido-heteroarildihidropirimidinas para el tratamiento y profilaxis de la infección del virus de la hepatitis b
EA201591027A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
DOP2012000243A (es) Compuestos de sililo tricíclicos fusionados y uso de los mismos en la fabricación de medicamentos útiles en el tratamiento de enfermedades virales
GT201300293A (es) 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina.
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
CO6290682A2 (es) Compuestos triciclicos fusionados inhibidores del virus de la hepatitis c.
UY32721A (es) Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados
UY32715A (es) Combinaciones farmacéuticas útiles para el tratamiento del virus de la hepatitis c (vhc), usos y métodos relacionados
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
UY32720A (es) Combinaciones farmaceuticas utiles para el tratamiento del virus de la hepatitis c (vhc), usos y metodos relacionados
CU20210061A7 (es) Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer
BR112014015582A8 (pt) compostos antivirais
BR112015000392A2 (pt) novos indazóis para o tratamento e profilaxia da infecção por vírus sincicial respiratório
NI201400025A (es) Inhibidores de aplicación viral

Legal Events

Date Code Title Description
FG Grant or registration